Catalyst
Slingshot members are tracking this event:
Clovis Oncology (CLVS) discloses termination of Phase 2 ATLAS study of Rubraca (rucaparib) alone in relapsed/metastatic bladder cancer due to lack of efficacy
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| CLVS | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 12, 2019
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Rubraca, Rucaparib, Bladder Cancer, Termination
